Group Leader

Research Group Home Page: 

Work address: 
Cancer Research UK Cambridge Institute University of Cambridge Li Ka Shing Centre Robinson Way Cambridge CB2 0RE
Publications: 

Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma.

E-pub date: 01 Jun 2015


BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model.

E-pub date: 31 Jan 2015


p53 mutations change phosphatidylinositol acyl chain composition.

E-pub date: 31 Dec 2014


ADAM8 as a drug target in pancreatic cancer.

E-pub date: 31 Dec 2014


Organoid models of human and mouse ductal pancreatic cancer.

E-pub date: 31 Dec 2014


The RAS and YAP1 dance, who is leading?

E-pub date: 31 Oct 2014


Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions.

E-pub date: 01 Jul 2013


Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.

E-pub date: 31 Jan 2013


Corrigendum: The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.

E-pub date: 31 Dec 2012


Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.

E-pub date: 31 Oct 2012


The pancreas cancer microenvironment.

E-pub date: 31 Jul 2012


Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice.

E-pub date: 01 Jun 2012


What we have learned about pancreatic cancer from mouse models.

E-pub date: 01 May 2012


The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.

E-pub date: 31 Mar 2012


nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

E-pub date: 31 Mar 2012


Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma.

E-pub date: 12 Mar 2012


Predictive in vivo animal models and translation to clinical trials.

E-pub date: 01 Mar 2012


Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer.

E-pub date: 29 Feb 2012


Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials.

E-pub date: 31 Jan 2012


Understanding metastasis in pancreatic cancer: a call for new clinical approaches.

E-pub date: 31 Dec 2011


Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.

E-pub date: 01 Dec 2011


A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.

E-pub date: 01 Nov 2011


SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia.

E-pub date: 01 Nov 2011


Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression.

E-pub date: 01 Oct 2011


In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma.

E-pub date: 30 Sep 2011


C-Raf is required for the initiation of lung cancer by K-Ras(G12D).

E-pub date: 01 Jul 2011


Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis.

E-pub date: 30 Jun 2011


Stromal biology and therapy in pancreatic cancer.

E-pub date: 01 Jun 2011


Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.

E-pub date: 31 Dec 2010


Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha.

E-pub date: 05 Nov 2010


Deploying mouse models of pancreatic cancer for chemoprevention studies.

E-pub date: 01 Nov 2010


Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer.

E-pub date: 31 Oct 2010


C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).

E-pub date: 31 Oct 2009


RAS in cellular transformation and senescence.

E-pub date: 01 Sep 2009


Finding and killing the CRABs of pancreatic cancer.

E-pub date: 01 Sep 2009


Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.

E-pub date: 12 Jun 2009


An shRNA silencing a non-toxic transgene reduces nutrient consumption and increases production of adenoviral vectors in a novel packaging cell.

E-pub date: 01 May 2009


Modelling oncogenic Ras/Raf signalling in the mouse.

E-pub date: 01 Feb 2009


The use of GEM models for experimental cancer therapeutics.

E-pub date: 01 Sep 2008


K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses.

E-pub date: 01 Aug 2008


A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.

E-pub date: 31 Jul 2008


Dynamics of the immune reaction to pancreatic cancer from inception to invasion.

E-pub date: 30 Sep 2007


Maximizing mouse cancer models.

E-pub date: 01 Sep 2007


Requirement for Rac1 in a K-ras induced lung cancer in the mouse.

E-pub date: 31 Aug 2007


The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.

E-pub date: 30 Jun 2007


Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways.

E-pub date: 31 May 2007


Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas.

E-pub date: 01 Mar 2007


Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis.

E-pub date: 28 Feb 2007


Restoration of p53 function leads to tumour regression in vivo.

E-pub date: 31 Jan 2007


Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.

E-pub date: 30 Nov 2006


The use of targeted mouse models for preclinical testing of novel cancer therapeutics.

E-pub date: 31 Aug 2006


Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.

E-pub date: 31 Aug 2006


Physiological analysis of oncogenic K-ras.

E-pub date: 01 Aug 2006


Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma.

E-pub date: 31 Dec 2005


Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations.

E-pub date: 31 Dec 2005


Pancreatic cancer in mice and man: the Penn Workshop 2004.

E-pub date: 31 Dec 2005


The differential effects of mutant p53 alleles on advanced murine lung cancer.

E-pub date: 31 Oct 2005


ATP citrate lyase inhibition can suppress tumor cell growth.

E-pub date: 01 Oct 2005


Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development.

E-pub date: 31 Aug 2005


Ductal pancreatic cancer in humans and mice.

E-pub date: 01 Aug 2005


Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.

E-pub date: 01 May 2005


VAV1: a new target in pancreatic cancer?

E-pub date: 01 May 2005


Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.

E-pub date: 28 Feb 2005


Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.

E-pub date: 30 Nov 2004


Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis.

E-pub date: 01 Nov 2004


Detecting and diagnosing ampullary neoplasms.

E-pub date: 01 Jul 2004


Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.

E-pub date: 01 Apr 2004


Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

E-pub date: 01 Feb 2004


Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

E-pub date: 31 Dec 2003


Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.

E-pub date: 01 Dec 2003


Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

E-pub date: 30 Nov 2003


BRAF as a potential therapeutic target in melanoma and other malignancies.

E-pub date: 31 Aug 2003


Targeting oncogene dependence and resistance.

E-pub date: 01 May 2003


Ras redux: rethinking how and where Ras acts.

E-pub date: 01 Feb 2003


In search of an early warning system for pancreatic cancer.

E-pub date: 01 Jan 2003


Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

E-pub date: 31 Jul 2002


Technologically advanced cancer modeling in mice.

E-pub date: 01 Feb 2002


Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

E-pub date: 30 Nov 2001


STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.

E-pub date: 31 Jul 2001


Signal transduction pathways in sarcoma as targets for therapeutic intervention.

E-pub date: 01 Jul 2001


Somatic activation of the K-ras oncogene causes early onset lung cancer in mice.

E-pub date: 31 Mar 2001


Modeling human lung cancer in mice: similarities and shortcomings.

E-pub date: 31 Aug 1999


CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase.

E-pub date: 30 Apr 1993


Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex.

E-pub date: 30 Apr 1991


Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19.

E-pub date: 31 Dec 1990


Show all